These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24930319)

  • 41. The unique role of transdermal buprenorphine in the global chronic pain epidemic.
    Pergolizzi JV; Scholten W; Smith KJ; Leighton-Scott J; Willis JC; Henningfield JE
    Acta Anaesthesiol Taiwan; 2015 Jun; 53(2):71-6. PubMed ID: 26205326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study].
    Muriel Villoria C; Pérez-Castejón Garrote JM; Sánchez Magro I; Neira Alvarez M
    Med Clin (Barc); 2007 Feb; 128(6):204-10. PubMed ID: 17335723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pain management in palliative cancer patients: a prospective observational study on the use of high dosages of transdermal buprenorphine.
    Clement PM; Beuselinck B; Mertens PG; Cornelissen P; Menten J
    Acta Clin Belg; 2013; 68(2):87-91. PubMed ID: 23967714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transdermal buprenorphine for the treatment of cancer pain: results from a multicenter, observational, post-marketing study in Spain (RELIEF study).
    Camps C; Casinello J; Virizuela JA; Escobar Y; Sanchez-Magro I; Stern A
    Pain Manag; 2011 Nov; 1(6):513-22. PubMed ID: 24645762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients.
    Daitch D; Daitch J; Novinson D; Frey M; Mitnick C; Pergolizzi J
    Pain Med; 2014 Dec; 15(12):2087-94. PubMed ID: 25220043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study.
    Gallagher AM; Leighton-Scott J; van Staa TP
    Clin Ther; 2009 Aug; 31(8):1707-15. PubMed ID: 19808129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient perceptions associated with the 5% lidocaine medicated plaster in daily practice.
    Überall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2012 Jun; 28(6):901-9. PubMed ID: 22506624
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R; Nuijten M; Nautrup BP
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.
    Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O;
    Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transdermal buprenorphine combined with spinal morphine and naropine for pain relief in chronic peripheral vasculopathy.
    Aurilio B; Pace MC; Passavanti MB
    Minerva Anestesiol; 2005; 71(7-8):445-9. PubMed ID: 16012418
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of transdermal buprenorphine patch in the elderly.
    Al-Tawil N; Odar-Cederlöf I; Berggren AC; Johnson HE; Persson J
    Eur J Clin Pharmacol; 2013 Feb; 69(2):143-9. PubMed ID: 22706617
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
    Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
    Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Buprenorphine: revisiting the efficacy of transdermal delivery system.
    Kitzmiller JP; Barnett CJ; Steiner NS; Stoicea N; Kamar N; Luzum JA; Mikulik E; Bergese SD
    Ther Deliv; 2015; 6(4):419-22. PubMed ID: 25996041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Buprenorphine for chronic pain.
    Calderon R; Copenhaver D
    J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):402-5. PubMed ID: 24245573
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
    Sittl R; Nuijten M; Poulsen Nautrup B
    Clin Ther; 2006 Aug; 28(8):1144-1154. PubMed ID: 16982291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clarification on transdermal buprenorphine.
    Dankiewicz EH; Haddox JD
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):415-6. PubMed ID: 25348227
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
    Steiner D; Munera C; Hale M; Ripa S; Landau C
    J Pain; 2011 Nov; 12(11):1163-73. PubMed ID: 21807566
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predicting medication persistence to buprenorphine transdermal system.
    Pergolizzi JV; Ben-Joseph R; Chang CL; Hess G
    Pain Pract; 2015 Feb; 15(2):140-9. PubMed ID: 24444055
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transdermal buprenorphine controls central neuropathic pain.
    Weiner M; Sarantopoulos C; Gordon E
    J Opioid Manag; 2012; 8(6):414-5. PubMed ID: 23264319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects.
    Wang Y; Cipriano A; Munera C; Harris SC
    J Clin Pharmacol; 2016 Oct; 56(10):1263-71. PubMed ID: 26865472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.